论文部分内容阅读
目的观察蔗糖铁注射液治疗腹膜透析患者肾性贫血的临床疗效。方法选择腹膜透析(CAPD)的患者48例分为静脉组和口服组各24例,两组均应用重组人红细胞生成素120~150u/kg,3次/周,皮下注射;静脉组应用蔗糖铁注射液100mg稀释于100 ml生理盐水中静脉滴注,2~3次/周;口服组应用琥珀亚酸铁口服,200mg/次,3次/天。结果两组患者治疗后血红蛋白、红细胞压积、铁蛋白较治疗前升高明显(P<0.05),静脉组血红蛋白(Hb)、红细胞压积(Hct)、血清铁蛋白(Sf)升高比口服组显著(P<0.01),贫血较口服组更容易纠正。静脉组未发现1例不良反应,口服组3例出现不良反应。结论静脉注射蔗糖铁能有效改善腹膜透析患者肾性贫血。
Objective To observe the clinical efficacy of sucrose iron injection in the treatment of renal anemia in peritoneal dialysis patients. Methods Forty-eight patients with peritoneal dialysis (CAPD) were divided into intravenous group and oral group, 24 cases in each group. The two groups were given recombinant human erythropoietin (120-150u / kg) three times a week for subcutaneous injection. Injection 100mg diluted in 100 ml of normal saline intravenously, 2 or 3 times / week; oral administration of succinic acid iron oral, 200mg / time, 3 times / day. Results After treatment, hemoglobin, hematocrit and ferritin were significantly increased in both groups (P <0.05). The levels of Hb, Hct and Sf in the venous group were significantly higher than those before treatment Group was significantly (P <0.01), anemia more easily corrected than the oral group. No adverse reactions were found in the venous group and 3 in the oral group. Conclusion Intravenous injection of sucrose iron can effectively improve renal anemia in peritoneal dialysis patients.